# An Investigation of the Effect of the Promoter Polymorphism in the Glucuronosyltransferase 2B7 in Patients on Breast Cancer Treatment

> **NCT00131612** · — · TERMINATED · sponsor: **AHS Cancer Control Alberta** · enrollment: 120 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** FEC 100

## Key facts

- **NCT ID:** NCT00131612
- **Lead sponsor:** AHS Cancer Control Alberta
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2002-01
- **Primary completion:** 2005-12
- **Final completion:** 2013-01
- **Target enrollment:** 120 (ACTUAL)
- **Why stopped:** did not apply for ethics renewal
- **Last updated:** 2016-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00131612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00131612, "An Investigation of the Effect of the Promoter Polymorphism in the Glucuronosyltransferase 2B7 in Patients on Breast Cancer Treatment". Retrieved via MORVS 2026-10-17 from https://api.morvs.ai/clinical/NCT00131612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*